Database-based screening combined with molecular docking simulations identifies API as a specific CDK1 inhibitor reversing NiNP-induced FAM dysregulation and tumor progression, clarifying NiNPs’ oncogenic potential and proposing a CDK1/FAM-targeted LUAD therapy with natural compounds. Here, CDK1 is linked to neoplasm.